This webinar will be hosted live and available on-demand
Wednesday, February 28, 2024
11:00 AM-12:00 PM Eastern Time
As the demands and requirements for new antibodies continue to evolve, access to broader antibody sequence diversity coupled with a powerful screening technology is critical. Unlike hybridoma and display technologies that can limit antibody diversity and require months to perform, Beacon® optofluidic technology enables rapid selection of lead candidates by function-first screening of single B cells to increase success rates and shorten antibody discovery timelines to days.
In this webinar brought to you by Bruker Cellular Analysis, Vincent Pai will present the full Beacon antibody discovery suite for screening primary plasma cells and memory B cells.
Topics to be covered
| Vincent Pai |
Sign up for the View from Westminster email for expert analysis straight to your inboxGet…
REVISITING THE SAGA OF THE CLOMAS, WHOSE FAR-SIGHTED VENTURES PROVIDED THE TRIGGER TO THE PHILIPPINE…
A newly elected MP who won his seat on a pro-Palestinian ticket once told a…
Despite updated guidelines advising against it, many older adults continue to use aspirin for cardiovascular…
A CELESTIAL SYMPHONY IN PAOAY, ILOCOS NORTE LOOK: The heavens unveiled a spectacular show on…
An environmental charity is calling for access to energy-efficient heating and cooling systems to be…
This website uses cookies.